Page 71 - Read Online

Ni et al. Hepatoma Res 2020;6:25 I http://dx.doi.org/10.20517/2394-5079.2020.14 Page 11 of 12

3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
4. Buonaguro L, Mauriello A, Cavalluzzo B, Petrizzo A, Tagliamonte M. Immunotherapy in hepatocellular carcinoma. Ann Hepatol
2019;18:291-7.
5. Brown ZJ, Greten TF, Heinrich B. Adjuvant treatment of hepatocellular carcinoma: prospect of immunotherapy. Hepatology
2019;70:1437-42.
6. Obeid JM, Kunk PR, Zaydfudim VM, Bullock TN, Slingluff CL, Jr., Rahma OE. Immunotherapy for hepatocellular carcinoma patients:
is it ready for prime time? Cancer Immunol Immunother 2018;67:161-74.
7. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate
040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
8. Leonardi GC, Candido S, Cervello M, Nicolosi D, Raiti F, et al. The tumor microenvironment in hepatocellular carcinoma (review). Int J
Oncol 2012;40:1733-47.
9. Zhang Q, He Y, Luo N, Patel SJ, Han Y, et al. Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell
2019;179:829-45.e20.
10. Chew V, Lai L, Pan L, Lim CJ, Li J, et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-
dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci U S A 2017;114:E5900-9.
11. Zhang Z, Ma L, Goswami S, Ma J, Zheng B, et al. Landscape of infiltrating B cells and their clinical significance in human hepatocellular
carcinoma. Oncoimmunology 2019;8:e1571388.
12. Ye L, Zhang Q, Cheng Y, Chen X, Wang G, et al. Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by
promoting TIM-1(+) regulatory B cell expansion. J Immunother Cancer 2018;6:145.
13. Xue H, Lin F, Tan H, Zhu ZQ, Zhang ZY, et al. Overrepresentation of IL-10-expressing B cells suppresses cytotoxic CD4+ T cell activity
in HBV-induced hepatocellular carcinoma. PLoS One 2016;11:e0154815.
14. Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med 2017;377:2500-1.
15. Ou DL, Lin YY, Hsu CL, Lin YY, Chen CW, et al. Development of a PD-L1-expressing orthotopic liver cancer model: implications for
immunotherapy for hepatocellular carcinoma. Liver Cancer 2019;8:155-71.
16. Zheng Y, Wang T, Tu X, Huang Y, Zhang H, et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with
hepatocellular carcinoma. J Immunother Cancer 2019;7:193.
17. Kaseb AO, Vence L, Blando J, Yadav SS, Ikoma N, et al. Immunologic correlates of pathologic complete response to preoperative
immunotherapy in hepatocellular carcinoma. Cancer Immunol Res 2019;7:1390-5.
18. Hong YK, Li Y, Pandit H, Li S, Pulliam Z, et al. Epigenetic modulation enhances immunotherapy for hepatocellular carcinoma. Cell
Immunol 2019;336:66-74.
19. Zhan C, Ruohoniemi D, Shanbhogue KP, Wei J, Welling TH, et al. Safety of combined yttrium-90 radioembolization and immune
checkpoint inhibitor immunotherapy for hepatocellular carcinoma. J Vasc Interv Radiol 2020;31:25-34.
20. Wesley JD, Whitmore J, Trager J, Sheikh N. An overview of sipuleucel-T: autologous cellular immunotherapy for prostate cancer. Hum
Vaccin Immunother 2012;8:520-7.
21. Gao F, Zhu HK, Zhu YB, Shan QN, Ling Q, et al. Predictive value of tumor markers in patients with recurrent hepatocellular carcinoma
in different vascular invasion pattern. Hepatobiliary Pancreat Dis Int 2016;15:371-7.
22. Shimizu Y, Suzuki T, Yoshikawa T, Endo I, Nakatsura T. Next-generation cancer immunotherapy targeting glypican-3. Front Oncol
2019;9:248.
23. Sang M, Wang L, Ding C, Zhou X, Wang B, et al. Melanoma-associated antigen genes - an update. Cancer Lett 2011;302:85-90.
24. Castelli C, Rivoltini L, Andreola G, Carrabba M, Renkvist N, et al. T-cell recognition of melanoma-associated antigens. J Cell Physiol
2000;182:323-31.
25. Wang K, Liu J, Yan ZL, Li J, Shi LH, et al. Overexpression of aspartyl-(asparaginyl)-beta-hydroxylase in hepatocellular carcinoma is
associated with worse surgical outcome. Hepatology 2010;52:164-73.
26. Lee JH, Lee Y, Lee M, Heo MK, Song JS, et al. A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic
cells in patients with hepatocellular carcinoma. Br J Cancer 2015;113:1666-76.
27. Lee JH, Tak WY, Lee Y, Heo MK, Song JS, et al. Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma,
randomized phase II study. Oncoimmunology 2017;6:e1328335.
28. Zhou Y, Liu F, Li C, Shi G, Xu X, et al. Construction and characterization of adenovirus vectors encoding aspartate-beta-hydroxylase to
preliminary application in immunotherapy of hepatocellular carcinoma. J Immunol Res 2018;2018:9832467.
29. Chen C, Ma YH, Zhang YT, Zhang F, Zhou N, et al. Effect of dendritic cell-based immunotherapy on hepatocellular carcinoma: a
systematic review and meta-analysis. Cytotherapy 2018;20:975-89.
30. Mo HY, Liao YY, You XM, Cucchetti A, Yuan BH, et al. Timely meta-analysis on the efficacy of adoptive immunotherapy for
hepatocellular carcinoma patients after curative therapy. PLoS One 2017;12:e0174222.
31. Ding M, Wang Y, Chi J, Wang T, Tang X, et al. Is adjuvant cellular immunotherapy essential after TACE-predominant minimally-invasive
treatment for hepatocellular carcinoma? A systematic meta-analysis of studies including 1774 patients. PLoS One 2016;11:e0168798.
32. Liu Y, Chen X, Han W, Zhang Y. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of
leukemia. Drugs Today (Barc) 2017;53:597-608.
33. Gao H, Li K, Tu H, Pan X, Jiang H, Shi B, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular
carcinoma. Clin Cancer Res 2014;20:6418-28.
34. Jiang Z, Jiang X, Chen S, Lai Y, Wei X, et al. Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of